Sector News

IDEX Corporation appoints Mark A. Beck to Board of Directors

January 3, 2018
Life sciences

IDEX Corporation announced today the appointment of Mark A. Beck to the company’s Board of Directors, effective January 1, 2018.

“We are thrilled to welcome Mark to our Board of Directors,” said IDEX Chairman and Chief Executive Officer Andrew Silvernail. “His experience as a chief executive officer of a public company with significant international operations and his track record of innovation and successfully integrating acquired businesses will be a tremendous asset to IDEX. Mark is a values-based, results-oriented leader, making him a great fit with our Board and management.”

Beck has served as President and Chief Executive Officer of JELD-WEN Holding, Inc. (“JELD-WEN”), one of the world’s largest door and window manufacturers, since November 2015, and was appointed as a Director of JELD-WEN in May 2016. He joined JELD-WEN from Danaher Corporation, where he served as Executive Vice President, leading Danaher’s Water Quality and Dental platforms, beginning in April 2014. Previously, he spent 18 years with Corning Incorporated in a series of management positions with increasing responsibility, culminating in his appointment as Executive Vice President overseeing Corning’s Environmental Technologies and Life Science units in July 2012. He also served on the board of directors of Dow-Corning Corporation from 2010 to 2014. Beck holds a B.A. in Business Management from Pacific University and an M.B.A. from Harvard Business School.

Source: IDEX

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).